Abstract Body

Background: There is a renewed enthusiasm for a “cure research” aimed at understanding the mechanisms of HIV-1 persistence and developing therapeutic strategies to reduce and ultimately eliminate viral reservoirs. Limitations of human clinical studies make it imperative to develop analogous and tractable animal models for cure research. However, a major limitation of animal use is that SIV infection in rhesus macaques (RMs) is more virulent than HIV-1 and very difficult to control with antiretroviral therapy (ART). We have identified new SIVsmm strains that are less virulent in RMs and more closely reproduce the pathogenesis of HIV-1. Our hypothesis was that these new strains can be more readily controlled with ART. Our goal was therefore to achieve control of SIV replication in RMs by employing conventional ART regimens.

Methodology: Nine RMs (MaMu A*01, B*08, B17 neg and Trim5a matched) were iv infected with a newly derived transmitted-founder infectious molecular clone of the SIVsmmFTq strain that was never adapted in vitro. At 65 days postinfection (dpi), ART was initiated in four RMs (PMPA, 20 mg/kg/day; FTC, 40 mg/kg/day; integrase inhibitor L870812, 20 mg/kg bid). ART impact on viral replication was assessed by measuring plasma viral load (VL), as well as monitoring the memory CD4+ T cells in the intestine, the levels of T cell immune activation and proliferation, and biomarkers associated with disease progression in RMs: C-reactive protein, D-dimer, IL-6 and sCD14.

Results: All RMs become persistently infected with SIVsmmFTq. VL peaked at 10 dpi at 7-8 logs/ml and reached a set-point of 4.2-5.4 logs/ml by 42 dpi. After initiation of ART, VL decreased by 1.5-2 logs in 48 hours, followed by a slower decline to undetectable levels (<30 copies/ml) that were reached by 30 days post-treatment initiation. Over the next four months, VLs remained undetectable, without blips >30 copies/ml. Restoration of mucosal memory CD4+ T cells and reduction in immune activation wasobserved in RMs receiving ART but not in untreated controls. ART also normalized biomarkers associated with disease progression and mortality in RMs.

Conclusions: We established a robust macaque model of ART suppression with a three drug antiretroviral regimen that is analogous to current ART employed for HIV-1 infection. This simplified animal model of ART will permit evaluation of interventions targeting persistent viral reservoirs that are obstacles to a cure.